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ABSTRACT 
 
 Coronary artery disease is the leading cause of death in industrialized countries. 
Strategies to treat atherosclerotic coronary artery disease include coronary artery bypass grafting, 
which is often complicated by vein graft occlusion or stenosis. Severely occluded vein grafts can 
completely obstruct blood flow to the myocardium, resulting in a myocardial infarction, and 
eventually lead to heart failure. Heterotopic heart transplantation remains the treatment of choice 
for end-stage heart failure, however its widespread applicability is limited by the chronic 
shortage of donor organs. 
The therapeutic potential of stem cells in cardiac repair following myocardial infarction 
has generated a great deal of interest. Many types of stem/progenitor cells including embryonic 
stem cells and bone marrow-derived mesenchymal stem cells (MSCs) have been used to 
regenerate the infracted heart with promising results.  
Adipose tissue is an abundant source of multipotent stem cells that can be easily obtained 
from liposuction waste tissue. The yield of stem cells per gram of fat is higher when compared 
with marrow-derived MSCs, making adipose tissue an attractive source of autologous stem cells 
for cardiovascular cell therapies. The goal of this research effort was to examine the 
differentiation potential of adipose-derived stem cells (ASCs) along the leiomyogenic and 
cardiomyogenic lineages. 
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University of Pittsburgh, 2007 
 v 
ASCs were extracted from human subcutaneous adipose tissue from female donors 
during elective abdominoplasty, cultured in the presence of biomolecules responsible for 
vascular and cardiac development, and subjected to uniaxial cyclic strain in magnitudes 
comparable to the in vivo conditions. Protein and gene expression of smooth muscle- and 
cardiomyocyte-specific markers were assessed via immunoctytochemistry, Western blot 
analysis, and RT-PCR. Our results indicated that uniaxial cyclic strain inhibited cell 
proliferation, resulted in alignment of ASCs perpendicular to the direction of strain, and down-
regulated protein expression of early smooth muscle cell markers α-SMA and h1-calponin. 
Transforming growth factor β-1 significantly up-regulated the expression of α-SMA and h1-
calponin in ASCs. Cardiac-specific proteins sarcomeric α-actinin, troponin-I, troponin-T were 
undetected in ASCs exposed to demethylation agent 5-azacytidine. Expression of cardiac 
transcription factors Nkx2.5 and GATA4 were also absent. These results suggest that human 
ASCs may not be capable of cardiomyogenic differentiation via exposure to 5-azacytidine.   
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1.0  INTRODUCTION 
 Stem cells have great potential for use in tissue repair and regeneration. There has been 
continuing and incrementing interest in both the biology and potential therapeutic applications of 
adult stem cells. Bone marrow-derived mesenchymal stem cells are the most extensively 
characterized stem cell population derived from an adult tissue, and have been shown to 
differentiate into a wide range of cell phenotypes, including fat, bone, cartilage, muscle, and 
neural progenitors. The recent discovery and characterization of multilineage cells from adipose 
tissue has been met with a great deal of excitement by the field of tissue engineering and 
regenerative medicine. Even though studies have shown that nascent stem cells exist in other 
adult tissues, including the brain, dermis, skeletal muscle, and vasculature, adipose tissue is the 
most abundant and accessible source of adult stem cells. The work of this thesis examines the 
potential of adipose-derived stem cells in cardiovascular repair and the differentiation 
capabilities of these cells along the smooth muscle and cardiac lineages. 
1.1 GOALS AND CLINICAL MOTIVATION 
Coronary artery disease is the leading cause of death in the United States and other 
industrialized countries. The high impact of its main sequelae, acute myocardial infarction and 
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congestive heart failure, on the quality of life of patients and the cost of health care worldwide 
drives the search for new therapies.  
Current strategies to treat atherosclerotic coronary artery disease include coronary artery 
bypass grafting (CABG), in which autologous or synthetic grafts are used to bypass 
atherosclerotic vessels and restore blood flow to the ischemic myocardium. The grafts used 
include healthy arteries or veins harvested from a separate site, such as autologous saphenous 
vein and mammary artery grafts, or synthetic grafts made from Dacron or expanded 
polytetrafluoroethylene (ePTFE). Results with arterial grafts have been superior to venous grafts, 
however, suitable arterials grafts are scarce and harvest procedures add to morbidity and cost. 
Studies have shown that synthetic grafts can trigger immunologic reactions. Furthermore, 
autologous saphenous vein and mammary artery grafts often cannot be employed because of 
damage and pre-existing disease [1-2]. 
Complications from CABG include graft occlusion or stenosis [3], and 10-30% of 
patients suffer from thrombosis-related occlusions within the first month [4]. Furthermore, 95% 
of those patients require intervention within 10 years after the operation [4]. In fact, in patients 
who have had arterial or vein grafts, 40% of the grafts are severely obstructed 10 years after the 
initial procedure [5].      
Severely occluded arteries or grafts can completely obstruct blood flow to the 
myocardium, leading to a myocardial infarction, accompanied by irreversible damage to the 
heart. Overtime, critical loss of cardiac tissue and impairment of left ventricular function can 
cause ineffective pumping of the heart, resulting in heart failure. 
Congestive heart failure (CHF) is a major medical challenge, with 4.9 million patients in 
the United States currently suffering from its effects [6]. The economic cost associated with CHF 
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is estimated to be $27.9 billion annually [6]. Current therapeutic strategies used to treat CHF 
include pharmaceutical intervention, short term mechanical cardiac support, and heart 
transplantation. As adult myocardium has low potential for repair and regeneration, the ability of 
pharmaceutical agents to improve cardiac function is limited as these reagents do not address the 
fundamental issue of cell loss [7]. 
Currently, heterotopic heart transplantation is the treatment of choice for end-stage heart 
failure. However, its application is severely limited by the availability of donor organs. Although 
the technique has been used for over 30 years, the long term outcome of patients is still 
complicated by problems of organ rejection, infection, and development of disorders caused by 
immunosuppressive regimens designed to modulate the rejection process [7]. Clearly, there is a 
need for improved treatment options.  
The therapeutic potential of stem cells in cardiac repair following myocardial infarction 
has generated a great deal of interest. Many types of stem/progenitor cells including embryonic 
stem cells and bone marrow-derived mesenchymal stem cells (MSCs) have been used to 
regenerate the infracted heart with promising results.  
1.2 THESIS OVERVIEW 
Adipose tissue is an abundant, accessible, and replenishable source of multipotent adult 
stem cells that can be easily obtained from discarded liposuction waste tissue. The yield of stem 
cells per gram of fat is much higher when compared with bone marrow-derived MSCs [26-27], 
making adipose tissue an attractive source of autologous stem cells for tissue engineering 
strategies and cell therapies. The goal of this research effort was to examine the leiomyogenic 
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and cardiomyogenic differentiation potential of human adult stem cells derived from adipose 
tissue. We hypothesized that human adipose-derived stem cells (ASCs) could be induced to 
express early smooth muscle and cardiac muscle markers via biochemical and mechanical 
modulation, and have potential use in cardiovascular cell therapies. The specific aims of this 
thesis are as follows: 
1.2.1 Specific Aim 1: Examine the effects of β-mercaptoethanol, ascorbic acid, retinoid 
acids, dibutyryl-cAMP, and transforming growth factor-β1 on early smooth muscle protein 
expression in human ASCs. 
 Various combinations of bioactive molecules responsible for vascular development, 
including β-mercaptoethanol (BME), ascorbic acid (AA), retinoic acid (AA), dibutyryl-cAMP 
(d-cAMP), and transforming growth factor-β1 (TGF-β1), were used to stimulate differentiation of 
ASCs into smooth muscle cells (SMCs). ASCs were extracted from superficial abdominal 
adipose tissue of young female donors undergoing elective abdominplasty. Response of ASCs to 
various exogenous biochemical stimuli and smooth muscle cell differentiation of ASCs were 
characterized by changes in cell morphology and protein expression of early SMC markers α-
smooth muscle actin (α-SMA) and calponin. We hypothesized that exposure to BME, AA, RA, 
d-cAMP, and TGF-β1 would result in up-regulation of α-SMA and calponin protein expression in 
human ASCs.   
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1.2.2 Specific Aim 2: Determine the effects of mechanical strain on ASC morphology, 
proliferation, and differentiation along the smooth muscle cell lineage.  
 The response of human ASCs to uniaxial cyclic strain and modulation of early smooth 
muscle protein expression (α-SMA and calponin) via mechanical stimulation was accessed in 
Aim 2. ASCs were subjected to 10% uniaxial cyclic strain for 7 days using a FlexcellTM FX-
4000T tension strain unit (strain parameters were chosen to simulate in vivo conditions). An 
identical source of adipose tissue was used in this study as previously described in Aim 1. The 
synergistic effect of chemical and mechanical stimulation on ASCs utilizing the optimized 
biochemical conditions defined in Aim 1 was also examined. We hypothesized a reduction in 
cell proliferation, altered cell morphology/orientation, and up-regulation of α-SMA and calponin 
protein expression in human ASCs that were exposed to 10% uniaxial cylic strain. We also 
expected amplified smooth muscle protein expression in ASCs that were stimulated with 
bioactive molecules in addition to strain.  
 
1.2.3 Specific Aim 3: Define the effects of DNA-demethylator 5-azacytidine on early 
cardiac muscle protein and gene expression in human ASCs.   
 The potential of ASCs to differentiate into cardiomyocyte-like cells for myocardial repair 
via exposure to DNA-demethylation agent 5-azacytidine was investigated in Aim 3. ASCs were 
exposed to 5-azacytidine for specified time periods using repeated exposure and single transient 
exposure treatment methods. Expression of cardiomyogenic transcription factors Nkx2.5, 
GATA4, and contractile, cardiac-specific proteins such as sarcomeric α-actinin, troponin I, 
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troponin T, and gap junction protein connexin-43 was characterized. We hypothesized that 
exposure to 5-azacytidine could result in up-regulation of early cardiac-specific markers, and 
small populations of contractile cell clusters in human ASCs.  
1.3 GUIDE TO REMAINING CHAPTERS 
Chapter 2: Background information on coronary artery disease, myocardial infarction, 
congestive heart failure, current and alternative treatment options, adult stem cells, stem cell 
therapies for cardiovascular repair/regeneration, adipose-derived stem cells – characteristics and 
differentiation potential. 
 
Chapter 3: Methodologies used to extract stem cell population from adipose tissue, design of 
chemical and mechanical stimulation experiments, molecular biology and tissue engineering 
techniques used to evaluate cell response to biochemical and mechanical stimuli. 
 
Chapter 4: Results obtained from treating adipose-derived stem cells with an array of bioactive 
molecules reported to be significant in regulating the phenotype of cells of the vasculature, from 
exposing adipose-derived stem cells to uniaxial cyclic strain (in magnitudes similar to what 
vascular smooth muscle cells are subjected to in vivo), from culturing the stem cells in the 
presence of a DNA-demethylation reagent 5-azacytidine, are presented in this chapter.      
 
Chapter 5: Discussion of results presented in the previous chapter; conclusion and future 
directions. 
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2.0  BACKGROUND 
2.1 CORONARY ARTERY DISEASE 
Despite recent progress in prevention and treatment, cardiovascular disease remains the 
leading cause of morbidity and mortality in industrialized countries. Coronary artery disease 
(CAD) is the most common form of cardiovascular disease, and accounts for over 900,000 
deaths in the United States annually among both men and women in major ethnic groups [1-2].  
Coronary artery disease is characterized by the presence of atherosclerosis in the epicardial 
coronary arteries. Atherosclerotic plaques, the hallmark of atherosclerosis, progressively narrow 
the coronary artery lumen and impair antegrade myocardial blood flow. The reduction in 
coronary artery blood flow may be symptomatic or asymptomatic, and may culminate in a 
myocardial infarction, depending on obstruction severity and the rapidity of development [1-2]. 
2.1.1 Treatment Options for CAD 
The most common form of treatment for atherosclerotic CAD is coronary artery bypass 
graft (CABG) surgery. Such surgical procedure frequently requires multiple bypasses, and 
commonly employs the patient’s internal mammary artery or saphenous vein to redirect blood 
flow around atherosclerotic vessels and restore blood flow to the ischemic myocardium. 
 8 
Synthetic grafts made of Dacron or expanded polytetrafluoroethylene (ePTFE) have also been 
used with some success.  
2.1.2 Complications of CABG 
More than 500,000 CABG procedures are performed every year in the United States, 
making this surgery one of the most commonly performed surgical procedures in this country [1-
2]. However, CABG is not without significant constrains and complications. Studies have shown 
that autologous saphenous vein and mammary artery grafts often cannot be used because of 
damage or pre-existing disease. Synthetic grafts are employed when native vessels are not ideal 
or available, but suffer from immunologic and thrombotic complications [3]. Graft occlusion or 
stenosis remains a major clinical concern: 10-30% of CABG patients suffer from thrombosis-
related occlusions within the first month, and 95% of those patients require intervention within 
10 years after the initial operation [4-5]. 
Severely occluded vein grafts can completely obstruct blood flow to the myocardium, 
leading to a myocardial infarction. Myocardial infarction is characterized by irreversible loss of 
cardiac tissue. The ischemia-induced necrosis of cardiomyocytes can result in scar formation and 
reduced contractility of the left ventricle, and eventually lead to total heart failure.  
2.1.3 Congestive Heart Failure and Heterotopic Heart Transplantation 
Despite significant progress in the prevention and treatment of cardiovascular disease in 
the past two decades, national statistics indicate that the incidence and prevalence of congestive 
heart failure (CHF) have been increasing steadily in recent years, especially in the elderly [6]. It 
is estimated that four to five million Americans suffer from heart failure and its related effects, 
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with 400,000 new cases occurring each year. CHF results in almost one million hospitalizations 
every year, and the economic cost associated with CHF is estimated to be $27.9 billion annually 
[6]. Moreover, prognosis is poor for CHF, with a median survival after onset of only 1.7 years in 
men and 3.2 years in women [7].  
Current therapeutic strategies used to treat CHF include pharmaceutical intervention, 
short term mechanical cardiac support, and heart transplantation. As adult myocardium has low 
potential for repair and regeneration, the ability of pharmaceutical agents to improve cardiac 
function is limited as these reagents do not address the fundamental issue of cell loss [7]. 
Currently, heterotopic heart transplantation is the treatment of choice for end-stage heart 
failure. Heart transplantation has a high success rate with a short-term survival of 81%, however 
its application is severely limited by the chronic shortage of donor organs [7]. Although the 
technique has been used for over 30 years, the long term outcome of patients is still complicated 
by problems of organ rejection, infection, and development of disorders caused by 
immunosuppressive regimens designed to modulate the rejection process [7]. Clearly, there is a 
need for improved treatment options. 
2.1.4 Cell Transplantation and Alternative Therapies 
A newly developed therapeutic strategy termed cell transplantation targets the issue of 
cell loss and consequent deterioration in heart function. Cell transplantation has been shown to 
be a promising alternative treatment for myocardial repair. Ideally, cell transplantation allows the 
replacement of diseased cardiomyocytes and scar tissue with fully functional cardiomyocytes, 
improving cardiac function, and thus relieving the symptoms of heart failure. To date, fetal 
cardiomyocytes [8-10], skeletal myoblasts [11-12], and smooth muscle cells [13] have been 
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successfully transplanted into normal and infracted myocardium in various animal models. All of 
these transplanted cells survived initially but were slowly eliminated due to immune rejection. 
Other sources of transplantable cardiomyocytes that have been described in literature include 
stem cells derived from neonatal or embryonic tissue [14] and marrow stromal cells [15-16]. 
2.2 STEM CELLS 
2.2.1 Embryonic Stem Cells vs. Mesenchymal Stem Cells derived from Adult Tissues 
Stem cells are immature tissue precursor cells that are able to self-renew and differentiate 
into multiple cell lineages. In recent years, considerable activity has focused on the potential 
therapeutic use of stem cells for repair of damaged adult organs, such as an impaired 
myocardium. The candidate cell types include totipotent juvenile cells, such as embryonic stem 
cells (ESCs), as well as multipotent stem cells derived from adult tissues, including cells from 
the bone marrow compartment, liver, neural tissue, pancreas, and skeletal myoblasts. While 
embryonic stem cells exhibit virtually unlimited differentiation potential both in vitro and in 
vivo, ethical and political concerns, and potential problems of cell regulation, have limited the 
use of ESCs [17-18]. In contrast, there is little ethical controversy surrounding adult stem cells. 
Increasing evidence on the ability of mesenchymal stem cells (MSCs) derived from adult tissues 
to differentiate outside their predicted developmental lineage has also added to the appeal of 
MSCs in cell-based therapies [19-20]. 
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2.2.2 Mesenchymal Stem Cells 
Mesenchymal stem cells (MSCs) have been isolated from bone marrow, skeletal muscle, 
skin, blood, adipose and brain tissue [21-26]. MSCs have been characterized by their plastic 
adherent growth and subsequent expansion under specific culture conditions, by a panel of 
nonspecific surface antigens and by their in vitro and in vivo differentiation potential [27]. 
Induction of differentiation into different cell types such as osteoblasts, adipocytes myoclasts, 
and chondrocytes under appropriate culture conditions has been demonstrated extensively [28-
31].  
2.2.3 Bone Marrow-derived Mesenchymal Stem Cells 
Much of the work conducted on adult stem cells has focused exclusively on 
mesenchymal stem cells found within the bone marrow stroma. The existence of hematopoietic 
stem cells (HSCs) within the bone marrow compartment was established decades ago. The idea 
of a separate non-hematopoietic stem cell population was recognized with the discovery of 
marrow derived cells that were capable of forming new bone and cartilage [32-34]. These cells, 
initially referred to as marrow stromal cells, were found to have the ability to also form cells and 
tissue of other lineages, leading to their ultimate characterization and classification as 
mesenchymal stem cells. 
2.2.4 Cell Yield and General Characteristics of Marrow-derived Mesenchymal Stem Cells 
MSCs are rare in bone marrow, representing only ~1 in 10,000 nucleated cells [26-27]. 
They are isolated from the marrow by a process involving Ficoll centrifugation and adhering cell 
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culture in defined serum-containing medium. These cells are obtained from vigorous washing of 
cells from bone marrow aspirates in culture as MSCs differentially adhere to the plastic culture 
dish. This technique has been used to isolate MSCs from humans, rats and mice. Removing cells 
with HSC or endothelial progenitor cell (EPC) markers by flow cytometry analysis or FACS 
prior to plating initial cultures enhances the specificity of this method. The resulting cells, while 
not immortal, have the ability to expand many-fold in culture, and retain their growth 
characteristics and multilineage potential [28, 35-36]. Individual MSC clones have the ability to 
differentiate to cartilage, bone, muscle, adipose and stromal tissues. Phenotypically, MSCs have 
been defined as CD29+, CD44+, CD90+, CD105+, and negative for hematopoietic lineage 
markers such as CD34 and CD45 [35-36]. 
    
2.3 ADIPOSE TISSUE AS AN ALTERNATIVE SOURCE OF ADULT STEM CELLS 
2.3.1 Adipose-derived Stem Cells - General Characteristics 
Adipose tissue, like bone marrow, is derived from the embryonic mesenchyme and 
contains a fibroblast-like stem cell population known as Adipose-derived Stem Cells (ASCs). 
ASCs are easily isolated from discarded liposuction tissue by collagenase digestion and 
differential centrifugation, and can be maintained in vitro for extended periods with stable 
population doubling and low levels of senescence [21-22]. The majority of these cells are of 
mesodermal or mesenchymal origin with low levels of contaminating pericytes, endothelial cells, 
and smooth muscle cells. It has also been reported that ASCs have the ability to differentiate 
along mesenchymal lineages in the presence of lineage-specific induction factors. Zuk et al [21-
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22] have demonstrated that these multipotent stromal cells could be chemically induced to 
differentiate into adipocytes, chondrocytes, and osteoblasts. Subsequent work by members of this 
group and others have confirmed and extended this work, demonstrating a capacity for myogenic 
[37], neuronal [38-39], and cardiomyocytic differentiation [40]. 
While there is some debate as to whether the cells originate in the adipose tissue or are 
perhaps mesenchymal or peripheral blood stem cells temporarily residing in the adipose tissue, 
ASCs represent a readily available source of potentially useful stem cells. The ASCs can be 
maintained for extended periods of time in culture, have a mesenchymal-like morphology, and 
demonstrate plasticity and multilineage potential in vitro [21-22, 37-40]. Adipose tissue is 
perhaps the most abundant and accessible source of adult stem cells that allows extraction of a 
large volume of tissue with low morbidity. The yield of stem cells per gram of fat is 
extraordinarily high, especially when compared to bone marrow-derived mesenchymal stem cells 
[26-27]. As human adipose tissue is plentiful, extraction of a large volume of tissue is possible 
with little patient discomfort and donor site morbidity, making adipose tissue a promising source 
of autologous stem cells for tissue engineering strategies and cellular therapies. 
2.3.2 Adipose-derived Stem Cell Isolation Methodology 
Adipose tissue is available in abundance and can be easily obtained from donors via 
common surgical procedures such as resection, conventional liposuction and ultrasound-assisted 
liposuction. All of the above surgical procedures result in minimal patient discomfort and donor 
site morbidity. Ultrasound-assisted liposuction was first introduced in 1987 by Scuderi et al. and 
uses ultrasonic energy to selectively destruct subcutaneous adipose tissue. Recent studies have 
compared the yield and growth characteristics of stem cells isolated from adipose tissue using 
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different types of surgical techniques and found that adipose-derived stem cells obtained by 
resection or traditional liposuction contain rapidly growing cell populations, whereas stem cells 
obtained by ultrasound-assisted liposuction exhibit low proliferative capacity (unpublished 
findings from our laboratory). In contrast, the surgical procedure used had no effect on the yield 
of viable stromal vascular fraction cells obtained from adipose tissue.  
Whole adipose tissue obtained via resection requires pre-processing or mincing the tissue 
into small fragments. Minced or liposuctioned adipose tissue is typically digested at 37ºC in a 
salt solution containing type II collagenase. The digested tissue is filtered to remove excessive 
tissue fragments and subjected to centrifugation to separate the different cellular components. 
The supernatant contains the mature adipocytes that are buoyant due to their lipid content, 
whereas the pellet contains the stromal vascular components including the adipocyte progenitor 
cells or multipotent stem cell population, in addition to hematopoietic lineage cells. An 
erythrocyte lysis buffer is used to remove the hematopoietic population. The resulting pellet is 
plated in regular cell culture media (1:1 DMEM/F12, supplemented with 10% FBS and 
antibiotics) with dexamethasone to inhibit fibroblast growth and contamination. After 4-6 hrs 
post cell isolation, the stem cells are washed with saline solution to remove contaminating 
adipocytes and fragments of adipose tissue. 
2.3.3 Surface Protein Characterization and Phenotype 
Adipose-derived stem cells share many properties with bone marrow-derived 
msenchymal stem cells.  While an extensive body of work exists pertaining to the phenotypic 
characterization of marrow-derived MSCs, the phenotypic characterization of ASCs is still in its 
infancy. ASCs express cell surface markers that are similar to those expressed by marrow-
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derived MSCs, including CD105, SH3, Stro-1, CD90, and CD44, but ASCs do not express the 
hematopoietic marker CD45 nor the endothelial marker CD31 [41-43]. Studies in which both 
bone marrow and adipose tissue were obtained from the same individuals, differences in protein 
expression were noted: ASCs express CD49d and not CD106, whereas marrow-derived MSCs 
express CD106 but not CD49d [41]. There is some controversy in literature regarding the 
expression of CD34, a widely used marker of hematopoietic stem and progenitor cells, by ASCs. 
CD34 is highly expressed in vascular endothelial cells and precursors. Groups have shown that 
the expression of CD34 is low to absent in cultured ASCs [21,43], whereas other groups [42,44] 
have reported higher levels of CD34 expression.  
 
2.4 DIFFERENTIATION CAPACITY OF ADIPOSE-DERIVED STEM CELLS 
2.4.1 Adipogenesis 
ASCs have the ability to revert to their original differentiation pathway, which is 
adipogenesis. When cultured in induction cocktails containing insulin, methylisobutylxanthine, 
hydrocortisone, dexamethasone, and/or indomethacin for 7-10 days, ASCs collect lipid vacuoles, 
as detected by Oil Red O. ASCs also express several adipocytic genes or proteins including 
lipoprotein lipase, aP2, PPARgamma2, leptin, and Glut4 [21-22,45-47].  
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2.4.2 Osteogenesis 
The ability of MSCs to give rise to osteoblasts has been extensively studied [48-50]. 
Several groups have isolated stem cells from adipose tissue from humans and other species, and 
have successfully differentiated them into osteoblasts in vitro. ASCs have been shown to 
differentiate into osteoblast-like cells in the presence of ascorbate, beta-glycerophosphate, 
dexamethasone and vitamin D3, and bone morphogenic protein (BMP-2) [51-52]. After 2-4 
weeks in culture, ASCs have been observed to deposit calcium phosphate mineral within their 
extracellular matrix and express osteogenic genes and proteins, including alkaline phosphatase, 
bone morphogenic proteins and receptors, osteocalcin, osteonectin and osteopontin [51-53]. 
2.4.3 Chondrogenesis 
ASCs can be induced to express markers associated with mature chondrocytes. After 
ASCs are exposed to transforming growth factor-β (TGF- β), ascorbate, and dexamethasone for 
1-2 weeks, ASCs begin to secrete the extracellular matrix proteins of cartilage, collagen type II, 
collagen type VI, and aggrecan (only when maintained in an appropriate 3D construct) [21,54-
56]. Interestingly, when ASCs are maintained in a monolayer under the same chondrogenic 
culture conditions, the expression of chondrocytic markers is greatly reduced [55].    
2.4.4 Neurogenesis 
Early studies have suggested that ASCs can express neuronal and/or oligodendrocytic 
markers. When exposed to antioxidants in the absence of serum, human and murine ASCs have 
been shown to assume a morphology similar to that of neuronal cells. This is accompanied by the 
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expression of neuronal associated proteins nestin, intermediate filament M, and Neu N, as well 
as glial fibrillary acidic protein. Exposure to indomethacin, insulin, and isobutylmethylxanthine 
results in a similar phenotype [38-39,21-22]. Recently, a number of groups have challenged such 
findings, suggesting that the changes in cell morphology were a mere response to toxic reagents. 
To date, no published study has been able to demonstrate the expression of mature neural 
markers, nor the ability of ASCs to form synaptic junctions and the generation or transmission of 
an action potential. 
2.4.5 Skeletal Myogenesis 
Studies have shown that culturing ASCs in the presence of dexamethasone and 
hydrocortisone results in a time dependent increase in the expression of muscle-specific markers 
(MyoD1 and myosin), expression of transcription factors (myogenin) responsible for regulating 
skeletal muscle differentiation [21-22,37]. Under these conditions, ASCs have been shown to 
fuse and form multi-nucleated structures that closely resemble myotubes. 
2.4.6 Epithelial Differentiation 
A recent study performed by Brzoska et al. [57] examined the potential of ASCs to 
differentiate toward the epithelial lineage via the use of retinoids. In this study, the effects of all-
trans retinoic acid (ATRC) on ASCs were investigated. The proliferation and viability studies 
with ATRA showed that at a concentration of 5μM an inhibitory effect on cell proliferation was 
evident. Further studies revealed that ASCs can be induced to express cytokeratin 18, an 
epithelial cytokeratin.  
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2.4.7 Hepatic Differentiation 
Another recent study [58] examined whether human adipose tissue-derived stromal cells 
can differentiate into hepatocyte-like cells in vitro for use in hepatocyte regeneration or liver cell 
transplantation. Human ASCs were treated with cytokines (HGF and OSM) that have been 
reported to be involved in the development and differentiation of hepatocytes. The addition of 
DMSO to the cytokine mixture was also reported to enhance hepatic differentiation. The 
differentiated cells showed LDL uptake and urea production, and expressed albumin and alpha-
fetoprotein. 
 
2.5 PLASTICITY OF ADIPOSE-DERIVED STEM CELLS TOWARD CELLS OF 
THE CARDIOVASCULAR LINEAGE 
Mature blood vessel walls have a complex three-dimensional structural organization that 
reflects compartments of highly differentiated cells and their associated extracellular matrix. The 
endothelial cells (ECs) that line the lumen are separated from the smooth muscle cells (SMCs) 
containing medial layer by a sub-endothelial extracellular matrix and the internal elastic lamina. 
Medial SMCs are arranged in concentric lamellar layers that are separated by an elastic fiber rich 
matrix. Fibroblasts of the outer collagen rich adventitial layer are, in turn, separated from media 
SMCs by the outer elastic lamina [59-60]. Recent studies have demonstrated that adult bone 
marrow stromal cell populations have the potential to differentiate into cells characteristic of 
blood vessels, in addition to bone, cartilage, muscle, fat and neural tissues. Similar studies have 
been applied to adipose-derived stem cells.    
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The adult heart is often referred to as a post-mitotic organ. Although components of the 
heart (endothelial cells, smooth muscles, and fibroblasts) are known to proliferate, the cells that 
make up the bulk of the heart, the myocardium, are thought to be terminally differentiated and 
have limited ability to regenerate. Bone marrow-derived mesenchymal stem cells have been 
shown to differentiate into cells displaying features of cardiomyocyte-like cells after exposure to 
a variety of chemical stimuli. However, studies conducted by other investigators have failed to 
reproduce these findings [115-116]. Adipose-derived stem cells from rabbit, murine and human 
adipose tissue have also been shown to be capable of cardiomyogenic differentiation [40, 95-96]. 
2.5.1 Endothelial Cells 
Miranville et al. performed a series of studies using CD34+/CD31- cells isolated from 
human adipose tissue, and demonstrated the ability of these cells to undergo in vitro and in vivo 
endothelial differentiation [61].  In these studies cultures of selected cells were grown in low 
serum medium supplemented with vascular endothelial growth factor (VEGF) and insulin-like 
growth factor 1 (IGF-1), forming network-like structures that expressed endothelial markers. Cao 
et al. isolated CD31-, CD34-, CD106- (VCAM-1-) and Flk+ cells from human adipose tissue and 
reported characteristics of endothelial progenitor cells [62]. Similarly, ASCs were shown to 
express endothelial markers when cultured in the presence of VEGF. Planat-Benard et al. [63] 
reported that murine ASCs can differentiate into endothelial cells, incorporate into vessels and 
promote post-ischemic neovascularization in nude mice and vessel-like structure formation in 
Matrigel. These cells (CD34- and CD13+) were able to spontaneously express endothelial cell 
markers CD31 and von Willebrand factor when cultured in a semisolid medium. 
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2.5.2 Smooth Muscle Cells 
Smooth muscle cells are an important component of the vasculature. Differentiating 
smooth muscle is characterized by the sequential appearance of cytoskeletal and contractile 
proteins to yield the variety of phenotypes that typify SMCs in the adult [76]. Two states of 
differentiation (“synthetic” and “contractile”) are often described in literature, representing the 
ends of a spectrum of phenotypes ranging from the undifferentiated state expressing few smooth 
muscle-specific proteins, to the fully differentiated phenotype expressing the complete repertoire 
of contractile proteins [76]. One of the first smooth muscle markers to be expressed is α-smooth 
muscle actin, though its expression is not restricted to smooth muscle cells, it is an early marker 
that is present in developing and mature smooth muscle. Calponin is an additional downstream 
marker that is more specific to SMCs. SM-22α, caldesmon, smooth muscle tropomyosin present 
additional markers. The more recently discovered smoothelin and smooth muscle myosin heavy 
chain display a high degree of smooth muscle specificity, and are restricted to mature SMCs 
[76]. Expression of these late SMC markers ceases in cultured smooth muscle cells.   
Smooth muscle cells are the subject of intense research in the field of cardiovascular cell 
therapies, however, finding a reliable source of SMCs is difficult. Biopsies of SMCs are morbid 
and impractical, making the search for alternative sources of healthy SMCs an urgent task. The 
use of stem cells has recently been suggested in smooth muscle repair. There have been 
numerous publications on the differentiation of marrow-derived MSCs and other progenitor cells 
into smooth muscle-like cells. The ability of ASCs to differentiate into SMCs has been less 
studied; there is only one publication to date on the capability of ASCs to differentiate into 
SMCs [71].  
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2.5.2.1 Previous Work on Smooth Muscle Cell Differentiation via Chemical Modulation 
In 2000, Arakawa et al. reported that a rat bone marrow stromal cell line TBR-B 
differentiates into SMCs when cultured in the presence of β-mercaptoethanol (BME) and 
ascorbic acid (AA) [64]. A follow-up study performed by the same group further examined the 
dosage-dependent manner of ascorbic acid on the expression of smooth muscle-specific markers 
in rat VSMCs [65]. Suzuki et al., reported that pluripotent murine embryonal carcinoma P19 
cells (whose developmental potential resembles that of early embryonic cells), can differentiate 
into SMCs when cultured in high concentrations of retinoic acid (RA) [66].  Similarly, Drab et 
al. demonstrated that murine totipotent embryonic progenitor cells cultured with RA and 
dibutyryl-cyclic adenosine monophosphate (d-cAMP) also differentiate into SMCs and express 
SM-specific markers [67]. In 2002, Kinner et al. reported that the α-smooth muscle actin 
expression in human bone marrow stroma-derived mesenchymal stem cells can be regulated by 
transforming growth factor-β1 (TGF-β1) and platelet derived growth factor-BB (PDGF-BB) 
[68]. Recently, Wang et al. performed an elaborate proteomic profiling on human bone marrow 
mesenchymal stem cells upon TGF-β1 stimulation, and further demonstrated the role of TGF-β1 
in the differentiation of marrow-derived mesenchymal stem cells along the SMC lineage [69]. 
Using gene therapy, Abderrahim-Ferkoune et al. reported that the overexpression of aortic 
carboxypeptidase-like protein (ACLP) promotes transdifferentiation of established mouse 
preadipocyte clonal line 3T3-L1 cultured in BME and AA into smooth muscle-like cells, which 
express SM-specific markers such as SM22α, SM α-actin, SM-MHC, and caldesmon [70].    
A recent publication by Rodriguez et al. [71] examined the capacity of ASCs to 
differentiate into phenotypic and functional smooth muscle cells for repair of the urinary tract. 
The authors reported genetic expression of all smooth muscle cell markers and increased protein 
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expression of smooth muscle cell-specific α-actin, calponin, caldesmon, SM22, myosin heavy 
chain, and smoothelin, when ASCs were cultured in smooth muscle inductive medium (medium 
MCDB 131 from Sigma supplemented with 1% FBS and 100 units/mL heparin) for 6 weeks. In 
addition, ASC-derived smooth muscle-like cells were reported to exhibit the ability to contract 
and relax in response to pharmacologic agents [71].  
2.5.3 Effects of Mechanical Forces on Vascular Cell Phenotype 
It has been well documented that cells and tissues in their native environment are 
constantly subjected to various forms of mechanical stimulation (such as compression, tension 
and shear) that are necessary for their normal development and functions [72-74]. In vivo, the 
arterial vessel wall is continuously exposed to mechanical stresses. While vascular endothelial 
cells (ECs) are exposed to shear stress due to the nature of blood flow, vascular smooth muscle 
cells are subjected to significant cyclic mechanical strain in the circumferential direction 
throughout the cardiac cycle [75]. These mechanical stresses are likely to influence the 
physiology of these cells by contributing to regulation of growth and phenotypic state of these 
cells. 
Vascular SMCs populate the media of blood vessels and play important roles in both the 
control of vasoactivity and the remodeling of the vessel wall. SMCs are characterized by high 
expression levels of an array of contractile marker proteins such as α-smooth muscle actin (α-
SMA), h1-calponin, h-caldesmon, smoothelin, and smooth muscle myosin-heavy chain [76]. The 
phenotype and functions of vascular SMCs have been reported to be regulated by chemical 
factors such as TGF-β, and by mechanical factors such as cyclic strain [77-78]. Vascular SMCs 
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are known to change from a contractile to a synthetic phenotype in the absence of mechanical 
stimulation [78-79]. 
2.5.4 Response of Cultured Vascular Smooth Muscle Cells and Mesenchymal Stem Cells 
to Strain 
Several experimental models have been developed to study the effects of mechanical 
forces on cultured vascular SMCs. Instruments such as the Flexcell Strain Unit [80] allow the 
examination of the cellular responses of vascular SMCs cultured on deformable substrates to 
mechanical strain under well-defined conditions, both in isolation and in combination with other 
important factors such as individual growth factors and extracellular matrices. For example, the 
application of cyclic strain to cultured vascular SMCs has been shown to promote the SMC 
contractile phenotype. Recent studies demonstrated the findings on the effects of cyclic strain 
alone on SMC differentiation of bone marrow-derived progenitor cells [81], and reported that 
mechanical forces facilitate the expression of SMC-specific cytoskeletal proteins in marrow 
stromal cells [82]. In addition, Park et al. [83] have conducted a direct comparison of the effects 
induced by different modes of mechanical strains on MSCs. 
While the response of cultured vascular SMCs and progenitor cells such as bone marrow-
derived MSCs to mechanical forces has begun to be described in literature, the effects these 
forces on ASCs remain unexplored. Although many groups have documented the 
multipotentiality or plasticity of ASCs into various cell types with chemically defined mediums, 
it is not well understood what role mechanical forces play in the differentiation of ASCs. 
Furthermore, the potential of mechanical forces in combination with bioactive molecules has 
also been less studied. 
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2.5.5 Cardiomyocytes 
Cardiomyocytes are essential elements of myocardial tissue structure and function. In 
vivo, cardiomyocytes are arranged in clusters, strands, and sheets, which are surrounded by a 
dense network of connective tissue. Communication between cardiomyocytes is via gap junction 
proteins connexins. Connexin-43 is a member of the connexin family [123]. Mature 
cardiomyocytes express cardiac-specific troponin I and troponin T, subunits of the troponin 
complex that provides a calcium-sensitive molecular switch for the regulation of striated muscle 
contraction [122]. Tropomyosin, sarcomeric α-actinin, desmin, and α-myosin heavy chain are 
additional cardiac-specific markers. Cardiomyocytes also express several cardiac transcription 
factors, including Nkx2.5 and GATA-4. These transcription factors are expressed in pre-cardiac 
mesoderm and persist in the heart during development [122]. Nkx2.5 is a homeobox-containing 
gene that is essential for normal heart development and morphogenesis. GATA-4 is a 
downstream cardiac transcription factor that is hypothesized to regulate cardiomyogenic 
differentiation. The expression of Nkx2.5 and GATA-4 are highly restricted to the heart and 
heart progenitor cells even in the early developmental stage.     
2.5.5.1 Cardiomyogenic Differentiation of MSCs via Exposure to 5-azacytidine   
Cardiomyogenic differentiaton of MSCs was first suggested by Makino et al. [84] in 
experiments detailing spontaneous cardiomyocyte-like contraction in isolated marrow stromal 
cells treated with the DNA-methylating agent, 5-azacytidine. This cardiomyogenic cell line 
exhibited expression of required cardiomyocyte transcription factors, GATA4, Nkx2.5, and 
Mef2C, organized sarcomeric structure, and ventricular cardiomyocyte-like action potentials, as 
well as functional adrenergic and muscarinic receptors [84]. Similar results were reported by 
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other investigators, including data on human MSCs based on similar treatment with 5-
azacytidine [85-91, 92]. After exposure to 5-azacytidine, MSCs were reported to exhibit a 
myotube-like structure and a time-dependent competence to synchronously beat. In turn, electron 
microscopic analysis revealed a cardiomyocyte-like ultrastructure including typical sarcomeres, a 
centrally positioned nucleus, and atrial granules. These cells showed several functional features 
of developing cardiomyocytes, including the production of peptides and the expression of 
multiple structural and contractile proteins. They also displayed sinus node-like and ventricular 
cell-like action potentials [85-91, 92]. 
 
2.5.5.2 Plasticity of Adipose-derived Stem Cells Toward Cardiomyocytes 
ASCs have also been shown to be capable of in vitro differentiation into cardiomyocytes 
[40, 95-96]. The most compelling data was obtained by Planat-Bernard et al. [95] in which fresh 
murine adipose-derived cells were plated into semisolid culture. After three weeks in culture, 
colonies of spontaneously beating cells were observed. These cells exhibited several molecular, 
electrophysiologic, and pharmacologic properties of cardiomyocytes. Most studies to date have 
focused on the use of 5-azacytidine to induce cardiomyogenic differentiation in ASCs (although 
these studies have reported successful transformation of rabbit or mouse, and not human ASCs 
into pulsating cardiomyocyte-like cells). One recent study by Gaustad et al. [96] exposed ASCs 
to nuclear and cytoplasmic extracts of rat cardiomyocytes transiently and reported the protein 
expression of cardiac specific markers such as sarcomeric α-actinin, desmin, and cardiac 
troponin I. The expression of the gap junction protein connexin 43 was also observed. To the 
best of our knowledge, there are no reports describing the effects of 5-azacytidine on human 
ASCs. 
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2.5.5.3 Regeneration of Ischemic Myocardium with Adipose-derived Stem Cells 
Over the last several years, there has been a surge of data detailing the use of cell-based 
therapies for post-myocardial infarction treatment. While much of these initial studies focused 
upon the use of skeletal myoblasts or neonatal cardiomyocytes, recent evidence suggesting the 
cardiomyogenic potential of stem cell populations has shifted the focus of cell therapy towards 
myocardial regeneration with adult stem cells such as bone marrow-derived mesenchymal stem 
cells [124,125]. Since the first study conducted in 1999, marrow-derived mesenchymal stem 
cells have been shown to engraft in injured myocardium, express cardiac markers and assume 
cell morphology consistent with cardiac differentiation. In addition, animals that were treated 
with these stem cells have demonstrated improved cardiac function based on numerous clinical 
measures [124,125]. Several recent reports suggest that adipose-derived stem cells may be an 
equally promising source of cells for cardiac therapeutics. Early in vivo work conducted by 
Strem et al. [126] demonstrated that that intravascular injection of ASCs into mice following 
cryoinjury of the left ventricle resulted in positive engraftment of ASCs at the site of injury. 
Donor-derived cells expressed cardiac-specific transcription factor Nkx2.5, troponin I and 
myosin heavy chain, consistent with cardiomyocytic differentiation of ASCs in vivo. 
Cardiomyocytic differentiation is not the only mechanism by which the plasticity of ASCs could 
affect myocardial function after infarction. The therapeutic potential of ASC may be further 
enhanced through their effects on neovascularization. ASCs in culture are known to secrete a 
number of proangiogenic factors such as vascular endothelial growth factor (VEGF), 
transforming growth factor-β, and hepatocyte growth factor. Miranville et al. [61] showed ASCs 
(CD34+/CD31-) that were exposed to VEGF and insulin-like endothelial growth factor I (IGF-I) 
formed network-like structures expressing endothelial markers CD31 and von Willebrand’s 
factor. These cells also increased the rate of perfusion recovery in a murine surgical model of 
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hind limb ischemia. Other groups have reported that growth factor supplementation is not needed 
with unsorted cells, suggesting that ASCs are capable of expressing the necessary pro-angiogenic 
factors in a paracrine fashion. Although the exact mechanisms of the pro-angiogenic response of 
ASCs are not well understood, their ability to secrete cytokines, as well as their direct 
incorporation into new vasculature, have great potential in the repair/regeneration of ischemic 
tissues. More research is needed to understand the mechanisms by which ASCs impart their 
cardio-protective or cardio-regenerative effect on injured tissue.       
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3.0  MATERIALS AND METHODS 
3.1 ADIPOSE-DERIVED STEM CELL ISOLATION AND CULTURE 
 Adipose-derived stem cells (ASCs) were isolated from human subcutaneous adipose 
tissue harvested during elective abdominoplasty and cultured as previously described [21-22]. 
Briefly, the subcutaneous adipose tissue was minced and then digested in Hank’s Balanced Salt 
Solution containing 1 mg/mL type II collagenase and 3.5% fatty acid free BSA in a 37 °C 
shaking water bath until the mixture was homogeneous.  The digested tissue was filtered through 
a double-layered gauze filter (350 μm) and centrifuged at 1000 rpm for 10 min. After 
centrifugation, the resulting cell pellet was treated with Erythrocyte Lysis Buffer, vortexed, and 
centrifuged at 1000 rpm for 10 min. The cells were resuspended in regular cell culture media 
(1:1 DMEM/F12, supplemented with 10% FBS and antibiotics) and plated at a density of 5x104 
cells/cm2. Cell culture media was changed every two days until confluence. Cells were either 
passaged and/or frozen down for future experiments. Low passage cells (<P4) from female 
donors (between the ages of 31 to 51 years old, mean age 42.5 years old) were utilized for the 
biochemical differentiation experiments in Aim 1. ASCs from six individual patients were 
treated with BME and AA (n=6), whereas ASCs from three patients were exposed to RA alone, 
RA and d-cAMP, or PDGF-BB (n=3), and ASCs from four patients were treated with two 
different concentrations of TGF-β1 (n=4). We utilized P0 cells from a 20-year-old female donor 
and a 29-year-old female donor for all our mechanical stimulation experiments in Aim 2. Two 
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experiments were conducted using ASCs from the 29-year-old donor, and one additional 
experiment was performed using cells from the 20-year-old female (n=3, where n is the total 
number of experiments performed). ASCs (<P4) from the same 20-year-old female donor and an 
additional 35-year-old female donor were used for cardiomyogenic differentiation experiments in 
Aim 3. Two experiments were conducted on the 20-year-old donor, whereas one additional 
experiment was conducted with the 35-year-old patient (n=3, where n is the total number of 
experiments performed).   
3.2 SMOOTH MUSCLE CELL DIFFERENTIATION EXPERIMENTS VIA 
CHEMICAL MODULATION 
3.2.1 Effects of BME, AA, RA, d-cAMP, TGF-β1, and PDGF-BB on SMC Protein 
Expression in ASCs 
Low passage ASCs (P<4) were thawed and cultured in regular plating medium for 24 hrs 
before the cells were lifted and seeded either on 22 x 22 mm glass coverslips in 6-well 
polystyrene plates (immunofluorescence staining) or in 100 mm tissue culture dishes 
(immunoblots). At confluence, ASCs were exposed to media with reduced serum (DMEM/F12, 
5% FBS, 1% P/S, without dexamethasone) supplemented with one of the following chemicals or 
growth factors:  
 A) β-mercaptoethanol (BME), 50μM, and ascorbic acid (AA), 0.3mM; 
 B) retinoic acid (RA), 1μM; 
 C) retinoic acid (RA), 1μM, and dibutyryl-cyclic adenosine monophosphate (d- 
  cAMP), 0.5mM; 
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 D) transforming growth factor-β1 (TGF-β1), 1ng/mL, and10ng/mL; 
 E) platelet-derived growth factor-BB (PDGF-BB), 10ng/mL. 
The ASCs were treated with fresh differentiation media every two days for the duration 
of 7 days and 14 days. Controls were ASCs cultured in plating medium with 5% serum without 
additional supplements. At the end of each time point, glass coverslips were fixed in 2% 
paraformaldehyde for immunofluorescence staining, whereas cell lysates were collected for 
Western blot analysis for early smooth muscle cell marker α-SMA.  Plating medium with 1% 
serum was used for all studies involving TGF-β1. 
3.2.2 Collagen Gel Contraction Assay 
 Collagen gel contraction assay was performed as an additional measure of cell 
contractility on treatment groups (such as exposure to TGF-β1) with significant up-regulation in 
contractile smooth muscle cell protein expression. A sterile solution of acid-soluble type I 
collagen derived from rat tail tendon (BD Biosciences, Bedford, MA) was prepared according to 
the manufacturer’s recommendations. ASCs that have been exposed to 1ng/mL TGF-β1 were 
encapsulated in 1mg/mL type I collagen gel at 1x106 cells/mL. The collagen-cell mixture was 
dispensed into 6-well polystyrene tissue culture plates (2mL/well) and allowed to polymerize at 
37 °C for 30 minutes. Immediately after polymerization, 1mL of culture medium with reduced 
serum (1%) was added to each well. Controls were untreated ASCs cultured in regular plating 
media with 1% serum. Cells embedded in collagen gels were allowed to attach for 24 hrs before 
the gels were released with a microspatula. Photographs of the gels were taken at different time 
points (t=0 or before release, and t=1, 6, 24, 48 hr). The diameter of the gel surface was 
measured, and the reduction in gel diameter over different time points was quantified.    
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3.3 MECHANICAL STIMULATION EXPERIMENTS 
 Following protocols described by Hamilton et al. [81] on the response of rat bone 
marrow stromal cells (BMSCs) to uniaxial cyclic strain, ASCs were subjected to 10% uniaxial 
cyclic strain at 1Hz (to mimic physiological conditions) for 7 days, using an FX-4000T strain 
unit (Flexcell Corp., McKeesport, PA, USA). Cyclic strain was supplied through membrane 
distension induced by air vacuum suction at the bottom of the plate, causing the flexible plate to 
stretch across an ArctangleTM loading post. This created a uniform uniaxial strain with negligible 
fluid shear stress. A computer was used to control the strain frequency, magnitude, and duration 
of the experiment.  
 ASCs were seeded on type I collagen-coated flexible bottom plates at 40,000 cells per 
well 3 days prior to mechanical stimulation. Controls were ASCs prepared in an identical manner 
and cultured on unstrained type I collagen-coated flexible 6-well plates for 7 days. ASCs 
(strained and controls) were cultured in plating medium with 1% serum with medium changes 
every 2 days. The effects of strain on cell morphology, cell proliferation, cytoskeletal 
organization, and early smooth muscle cell protein expression (α-SMA and calponin) were 
examined. 
 In order to study the combined effect of chemical and biomechanical stimulation on cell 
differentiation, unstrained and strained ASCs were also treated with media containing 1 ng/mL 
TGF-β1 (R & D Systems, Minneapolis, MN, USA). Experiments conducted in Aim 1 
demonstrated that TGF-β1 at 1ng/mL and 10ng/mL induced similar levels of α-SMA expression 
in ASCs at 24, 48 h, and 7 days. 
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3.3.1 Cell Morphology 
After 7 days of uniaxial cyclic strain, strained and unstrained ASCs were fixed in 2% 
paraformaldehyde for 15 min, washed with PBS, then stained with Coomassie blue. Images were 
captured at a magnification of 20x. Cell morphology was qualitatively observed and quantified 
using Scion Image image analysis software (version 4.02 beta; Scion Image, Frederick, MD). 
Ten images from each culture condition were used. Standard gray-level thresholding techniques 
were applied to each image to identify the cell boundaries, with manual editing required. The cell 
long axis of each cell was identified and measured against a fixed axis at the base of each image 
to determine an angle of orientation, ranging from 0º (parallel to strain) to 90º (perpendicular to 
strain). Each membrane was held in the same global orientation.  
3.3.2 Cell Proliferation 
Unstrained and strained ASCs were fixed in 2% paraformaldehyde for 15 min, washed 
with PBS, permeabilized with 0.1% Triton X-100, and stained with 4’,6-diamidino-2-
phenylindole, dihydrochloride (DAPI) at 0.6 μg/mL to visualize the cell nuclei. Ten random 
fields of view of cells from each culture condition were captured at a magnification of 20x. The 
number of cells was counted and averaged to provide a single cell count. 
3.3.3 Visualization of Cytoskeleton 
Strained and unstrained ASCs were fixed in 2% paraformaldehyde for 15 min, rinsed 
with PBS, and permeabilized with 0.1% Triton X-100 for 15 min. The cells were then be 
incubated with FITC-phalloidin (Sigmal Aldrich, St. Louis, MO) at a dilution of 1:500 in PBS 
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for 1 hour. The cells were counter-stained with DAPI for visualization of the cell nuclei. Ten 
images were captured for each culture condition using an Olympus Provis fluorescence 
microscope (AX70). F-actin labeling resulted in visualization of the alignment of the F-actin 
stress fibers.  
3.4 CARDIOMYOGENIC DIFFERENTIATION EXPERIMENTS VIA EXPOSURE 
TO 5-AZACYTIDINE 
 ASCs used in this study were extracted from two donors: 20-year-old and 35-year-old 
female patients. ASCs were cultured as previously described in Section 3.1. Low passage ASCs 
(P<4) were seeded in 6-well polystyrene plates coated with type I collagen at 50,000 cells/well, 
100,000 cells/well, and 150,000 cells/well. ASCs were exposed to regular plating media (with 
10% serum, and without dexamethasone) supplemented with 5μM or 10μM of 5-azacytidine 
(Sigma Aldrich, St. Louis, MO). 5-azacytidine was dissolved in acetic acid:water (1:1 v/v) at 
5mg/mL. Once dissolved, this stock solution was further diluted in aqueous plating media, 
pH’ed, and filtered. ASCs were exposed to 5-azacytidine transiently for 24 hrs or repeatedly (one 
or three treatments per week) for up to 8 weeks in culture. Controls consisted of ASCs cultured 
under the same conditions without exposure to 5-azacytidine. Parallel experiments were 
conducted on non-collagen coated polystyrene well plates. Untreated and 5-azacytidine treated 
ASCs were examined daily using light microscopy to monitor changes in cell morphology. 
Protein expression of sarcomeric α-actinin, cardiac troponin I, troponin T, gap junction protein 
connexin 43 and cytoskeletal protein α-SMA at different time points was assessed via 
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immunocytochemistry and Western blot analysis. Expression of cardiac transcription factors 
Nkx2.5 and GATA4 was also examined. 
3.5 CHARACTERIZATION OF SMC AND CM PROTEIN EXPRESSION 
3.5.1 Immunofluorescence Staining 
At the termination of each experiment, cells were fixed in 2% paraformaldehyde for 15 
min at room temperature and immunostained according to standard immunocytochemistry 
protocols. Briefly, after washing twice with PBS, 0.1% Triton-X made in PBS was applied to the 
cells for 15 min, and then non-specific binding was blocked using Normal Donkey Serum (NDS) 
or Normal Goat Serum (NGS). Monoclonal antibody specific for α-SMA, h1-calponin, 
sarcomeric α-actinin (Sigma Aldrich, St. Louis, MO), connexin 43 (BD Biosciences, Bedford, 
MA), or troponin I/troponin T (abcam, Cambridge, MA) was applied for 60 min at room 
temperature, followed by incubation with fluorescent-tagged secondary antibody (Alexa 488) for 
60 min. After subsequent washes with PBS, stained cells were viewed by fluorescent microscopy 
(Olympus Provis). To provide a quick assessment of cell distribution, 4’,6-diamidino-2-
phenylindole, dihydrochloride (DAPI) (0.6 μg/mL) was used to stain the nuclei of cells. Protein 
expression was qualitatively observed through the inspection of immunofluorescent images.  
3.5.2 Western Blot Analysis 
Cell lysates were collected at the termination of each experiment from each culture 
condition. Briefly, cells were washed with PBS, then 300 μL detergent-based lysis buffer (M-
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PER Mammalian Protein Extraction Reagent, Pierce, Rockford, IL) and protease inhibitor 
cocktail (1:100 dilution, Sigma Aldrich, St. Louis, MO) were added to each 100 mm dish for 
collection of total cellular protein (or 100uL of lysis buffer + protease inhibitor cocktail/well of a 
6-well plate). Equal amounts of protein (5-20μg, depending on the protein being probed) from 
each sample were loaded into a 10% SDS-PAGE gel for gel electrophoresis. The separated 
proteins were transferred to a nitrocellulose membrane. The membrane was blocked in 5% non-
fat milk/PBS-Tween 20 solution at 4°C overnight followed by the application of monoclonal 
antibody specific for α-SMA, h1-calponin, sarcomeric α-actinin (Sigma Aldrich, St. Louis, MO), 
connexin 43 (BD Biosciences, Bedford, MA), or troponin I/troponin T (abcam, Cambridge, MA) 
in 5% non-fat milk/PBS-Tween 20. After incubation at room temperature for 1-1.5 hours, the 
secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) in 5% non-
fat milk/PBS-Tween 20 was applied for 1 hour. The membrane was washed three times with 
0.01% PBS/Tween 20 for 10 min after each antibody application. The proteins on the 
nitrocellulose membrane were detected with the ECL Plus detection system (Amersham 
Pharmacia Biotech, Piscataway, NJ), according to the manufacturer’s protocol. The resulting 
protein bands were quantified by volume summation of image pixels with NIH ImageJ 1.30v. 
3.6 RNA EXTRACTION AND RT-PCR ANALYSIS 
 Total RNA was extracted from control ASCs and 5-azacytidine treated ASCs using 
RNeasy Mini RNA extraction kit (Qiagen Inc., Alameda, CA) according to the manufacturer’s 
protocol.  
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 cDNA was synthesized from 120ng of total RNA using  200U of reverse transcriptase 
(SuperScript II), 50ng of random hexamers, 10mM dNTP, and 40U of RNAse inhibitor in 
buffers containing 25mM of MgCl2.  
 cDNA samples were subjected to PCR amplification with human-specific primers for 
cardiac transcription factors Nkx2.5 and GATA4, and housekeeping gene GAPDH. 2μL of DNA 
template was added to a PCR buffer mix containing 25mM MgCl2, 10mM dNTP, and 5U of Taq 
polymerase (Promega). cDNA of human fetal cardiomyocytes was used as a positive control. 
 PCR was performed over 42 cycles for Nkx2.5 and GATA4 (36 cycles for GAPDH) 
consisting of an initial denaturation at 95 °C for 5 minutes, then 95°C for 1 minute, 60 °C 
(Nkx2.5) or 55 °C (GATA4) for 30 seconds, 72 °C for 30 seconds, and was terminated by a final 
extension at 72 °C for 7 minutes. Housekeeping gene GAPDH was used as the control. The PCR 
products were size-fractionated by 2% agarose gel electrophoresis.    
3.7 STATISTICAL ANALYSIS  
 Statistical analysis was performed by use of unpaired, two-tailed t tests on different 
combinations of variables. Data were represented as mean ± SD. The threshold for statistical 
significance was set at p ≤ 0.05. In Aim 1 and Aim 2, optical density (OD) values of Western 
blot bands of α-SMA and calponin were normalized to the OD values of corresponding bands for 
GAPDH (which was used as an internal loading control). The resultant OD values of different 
treatment groups were then normalized to the control, where the percentage of increase/decrease 
in α-SMA or calponin protein expression relative to the control was computed. Statistical 
analysis was conducted on the normalized OD values, hence resulting in groups with zero 
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standard deviation. For Aim 3, statistical analysis was performed on OD values of the protein of 
interest divided by OD values of GAPDH (ratios of α-SMA/GAPDH or Cx-43/GAPDH). The 
resultant OD values were not normalized to the control.      
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4.0  RESULTS 
4.1 ISOLATION OF ADIPOSE-DERIVED STEM CELLS FROM HUMAN ADIPOSE 
TISSUE 
 
Adipose-derived stem cells were extracted from human subcutaneous adipose tissue 
harvested during elective abdominoplasty from healthy female subjects. Briefly, whole adipose 
tissue was minced, and subjected to enzymatic digestion and differential centrifugation. The 
resultant cell pellet contains a fibroblast-like stem cell population as depicted in Figure 1. The 
stem cells were cryopreserved until they were ready for use. 
 
 
 
Figure 1 Culture and isolation of adipose-derived stem cells from human adipose tissue. 
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4.2 EFFECTS OF BME, AA, RA, D-CAMP, TGF-β1, and PDGF-BB ON ASCS  
4.2.1 Characterization of SMC Protein Expression via Immunocytochemistry and 
Western Blot Analysis 
Isolated ASCs (P<4) were seeded into the wells of a 6-well tissue culture plate at 
confluence from female donors between the ages of 20-51.  Following a protocol previously 
described by Arakawa et al. [64-65] for rat bone marrow stromal cells, we have exposed ASCs to 
culture medium supplemented with β-mercaptoethanol (BME) (50 µM) and ascorbic acid  (AA) 
(0.3 mM) for 14 days with medium changes every two days. After 14 days, the medium was 
removed and the cells were fixed for immunofluorescence staining.  Our immunofluorescence 
staining results indicated that ASCs treated with BME and AA were positive for early SMC 
markers such as α-SMA.  
 
A B
 
Figure 2  α-SMA immunofluorescence staining (green) counterstained with DAPI (blue) after 14 
days. (a) Control, (b) BME and AA-treated ASCs. 
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Figure 3a Representative Western blot for α-SMA and corresponding GAPDH from ASCs 
treated with BME and AA for 14 days. 
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Figure 3b The optical densities (OD) of the Western blot bands were measured using Image J 
analysis software. BME and AA increased the expression of α-SMA by 26% over the controls. 
ASCs from six individual patients were treated with BME and AA (n=6). Overly saturated bands 
may have resulted in an underestimated difference. 
 
From Figure 2, it is clear that both the controls and the experimental group were positive 
for α-SMA, although the cells treated with both BME and AA were marked by the appearance of 
pronounced stress fibers, and appeared to be more confluent. Western blot analysis demonstrated 
that the addition of BME and AA to ASCs induced an average increase of 26% in α-SMA 
expression (Figure 3a and Figure 3b). 
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DC
A B
 
Figure 4 Immunofluorescence of ASCs for α-SMA (green) counterstained with DAPI (blue). (A) 
Control ASCs after 14 days.  (B) ASCs exposed to PDGF-BB for 14 days. (C) ASCs treated with 
RA. (D) ASCs treated with RA and d-cAMP. 
 
Our immunofluorescence staining (Figure 4) and Western blot results also suggested that 
PDGF-BB and d-cAMP may play a role in down-regulating the expression of α-SMA (Figure 5a 
and Figure 5b). Treatment of high concentration of RA without d-cAMP resulted in a slight 
increase (9%) in the expression of α-SMA. Overly saturated bands may have resulted in an 
underestimated difference. 
 
 
 
 
 
 
Figure 5a Representative Western blot for α-SMA and GAPDH from ASCs treated with PDGF-
BB, RA, RA and d-cAMP. 
α-SMA
GAPDH
CON PDGF-BB RA RA+d-cAMP
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Figure 5b Both PDGF-BB and RA and d-cAMP decreased the expression of α-SMA 
significantly (n=3, p<0.05). Treating ASCs with high concentration of RA alone slightly 
increased the expression of α-SMA by 9% over the controls (n=3, p<0.05). Overly saturated 
bands may have resulted in an underestimated difference. 
 
 
Furthermore, TGF-β1 alone had significant effects on α-SMA expression. Two different 
dosages of TGF-β1 (1 ng/mL and 10 ng/mL) induced similar levels of α-SMA expression in 
ASCs after only 24 hrs. Cells treated with 1 ng/mL or 10 ng/mL of TGF-β1 demonstrated a 100% 
increase in the expression of α-SMA (n=4, p<0.05) (Figure 6a and Figure 6b). 
 
 
CON 1ng/mL 10ng/mL
TGF-β1 TGF-β1
α-SMA
(n=4)
 
Figure 6a Representative Western blot for α-SMA and GAPDH from ASCs treated with 
different dosages of TGF-β1 (1ng/mL, 10ng/mL) for the duration of 24 hours. 
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Figure 6b TGF-β1 at 1ng/mL and 10ng/mL induced similar levels of α-SMA expression in ASCs 
after 24hrs. Cells treated with 1ng/mL or 10ng/mL of TGF-β1 showed a 100% increase in the 
expression of α-SMA (n=4, p<0.05). 
4.2.2 Characterization of Cell Contractility via Collagen Gel Contraction Assay 
 Collagen gel contraction assay was performed as an additional measure of cell 
contractility on treatment groups with significant up-regulation in contractile smooth muscle cell 
protein expression. Since TGF-β1 (at either 1ng/mL or 10ng/mL) induced a 100% increase in the 
expression of α-SMA over the control or untreated ASCs after 24hrs, ASCs that have been 
exposed to 1ng/mL TGF-β1 were encapsulated in 1mg/mL type I collagen gel, and subjected to 
the collagen gel contraction assay. The cells embedded in gels were allowed to attach for 24 hrs 
before the gels were released with a microspatula. Photographs of the gels were taken at different 
time points, before release (t=0), at 1hr, 6hr, 24hr, and 24hr after the gel was released as shown 
in Figure 7. The diameter of the gel surface was measured from the digital images, and the 
reduction in gel diameter over different time points was quantified and presented as a graph in 
Figure 8. TGF-β1 treated ASCs showed greater cell contraction over time as compared with 
control or untreated ASCs.   
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Figure 7 Representative digital photographs demonstrating the effects of TGF-β1 on collagen gel 
contractility of ASCs over time (at t=0, prior to gel release, and at t=1, 6, 24, 48hr). ASCs were 
treated with 1ng/mL TGF-β1 for 24hr. Controls were untreated ASCs cultured under the same 
conditions. 
 
 
 
 
 
 
 
 
 
Figure 8 Time course of the stimulatory effect of TGF-β1 on cell-mediated collagen gel 
contraction. Control ASCs or TGF-β1 treated ASCs were encapsulated in collagen gels and 
released, after which the change in gel diameter was measured. Data are mean gel diameter ±SD 
from three independent experiments. 
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4.2.3 Summary of Results 
The objective of this work was to study the response of ASCs to exogenous biochemical 
stimulation, and the potential of ASCs to differentiate toward the SMC lineage. 
Immunofluorescence staining and Western blot analysis detected protein expression of early 
SMC marker α-SMA in both control and experimental groups. Expression of α-SMA in ASCs 
significantly increased when treated with TGF-β1, while α-SMA expression only slightly 
increased in the presence of RA, BME and AA. Treatment with PDGF-BB, RA and d-cAMP 
decreased the expression of α-SMA significantly. Cell contractility of TGF-β1 treated cells was 
further characterized with collagen gel contraction assay. TGF-β1 treated ASCs showed greater 
cell contraction over time as compared with control or untreated ASCs.   
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4.3 RESPONSE OF ASCS TO UNIAXIAL CYCLIC STRAIN 
4.3.1 Cell Morphology and Proliferation 
Adipose-derived stem cells demonstrated responsiveness to mechanical loading by 
altering their morphology and proliferation and regulating their protein expression of early SMC 
markers. To determine the effect of uniaxial cyclic strain on cell morphology and organization, 
ASCs exposed to uniaxial cyclic strain for 7 days were analyzed with Scion image analysis 
software. Cyclic strain of 10% markedly altered the morphology and orientation of cells. After 
exposure to strain for a day, ASCs reoriented themselves perpendicular to the direction of strain, 
and the stress fibers also aligned in the same direction (Figure 9 and Figure 10).  
 
CON CON+TGF-β1
STR STR+TGF-β1  
Figure 9 Phase-contrast images of ASCs cultured under static conditions (with or without TGF-
β1) and ASCs that were subjected to 10% uniaxial strain for 7 days. The arrows point in the 
direction of strain. 
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In contrast, control ASCs were randomly oriented. The orientation angle frequency distribution 
shown in Figure 11 further confirmed these observations. In addition, strain caused alignment of 
the f-actin cytoskeleton, perpendicular to the direction of applied strain. This may be due to an 
adaptation process of the cells to minimize the amount of forces applied on cell bodies.  
 
CON
STR STR+TGF-β1
CON+TGF-β1
 
Figure 10 F-actin arrangement of ASCs in static culture or 10% uniaxial strain for 7 
days, cultured with or without TGF-β1. F-actin staining results of control ASCs or strained ASCs 
treated with TGF-β1 were counter-intuitive. Increased F-actin stress fibers were not observed in 
TGF-β1 treated cells. 
 
 
Moreover, unstrained and strained ASCs continued to proliferate throughout the duration 
of the experiment, although the strained ASCs seemed to proliferate at a lower rate compared 
with the controls. A trend towards a decrease in cell proliferation was observed and is shown in 
Figure 12.  
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Figure 11 Orientation angle frequency distribution of each culture condition. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Average number of cells from 10 fields of view for each culture condition. TGF-β1 
had no effect on cell proliferation (n=3). 
4.3.2 Characterization of SMC Protein Expression via Immunocytochemistry and 
Western Blot Analysis 
Immunofluorescence staining and Western blot analysis detected protein expression of 
early smooth muscle cell markers such as α-SMA and h1-calponin in both strained and 
T0
CON CON+TGF-β1 STR STR+TGF-β1
0
5
10
15
20
25
30
35
T0 CON CON+TGF-b1 STR STR+TGF-b1
A
ve
ra
ge
 #
 o
f c
el
ls
pe
r 1
0 
fie
ld
s 
of
 v
ie
w *
*
*
*
* p<0.05
A
ve
ra
ge
 #
 o
f c
el
ls
pe
r 1
0 
fie
ld
s 
of
 v
ie
w
A
ve
ra
ge
 #
 o
f c
el
ls
pe
r 1
0 
fie
ld
s 
of
 v
ie
w
 49 
unstrained ASCs. Immunostaining and Western blot results showed that 10% uniaxial strain 
alone downregulated α-SMA and h-1calponin protein expression.  
Results from Western blot analysis indicated that uniaxial cyclic strain significantly 
decreased α-SMA expression by 40-50% after 7 days when compared with unstrained static 
controls (Figure 14). 
 
CON
STR
CON+TGF-β1
STR+TGF-β1  
Figure 13 Immunofluorescence staining for α-SMA. After 7 days of 10% uniaxial cyclic strain, 
the controls & strained ASCs were stained for α-SMA. 
 
Western blot analysis for α-SMA further confirmed the immunofluorescence staining 
results. GAPDH was used as an internal loading control. The optical densities (OD’s) of the 
Western blot bands were measured using Image J & normalized to the control. ASCs that were 
treated with TGF-β1 had about a 1.5 fold increase in the expression of α-SMA over the control 
ASCs. Strain alone reduced the expression by about 50%. Strain & TGF-β1 combined increased 
the expression to about 50% above that of the control ASCs (~1 fold over that of the strain only 
group).     
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Figure 14a Western blot analysis for α-SMA further confirmed the immunofluorescence staining 
results. GAPDH was used as an internal loading control.  
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Figure 14b Western blot analysis for α-SMA further confirmed the immunofluorescence 
staining results. GAPDH was used as an internal loading control. The data shown here were 
based on three experiments (n=3) with cells from two donors. Overly saturated bands may have 
resulted in an underestimated difference. 
 
 
In addition, h1-calponin was downregulated by ~50% as evidenced by 
immunofluorescence staining (Figure 15) and Western blot analysis (Figure 16). Cells cultured 
under static conditions in media supplemented with TGF-β1 demonstrated a significant increase 
in the expression of α-SMA and h-1calponin, marked by the presence of pronounced actin stress 
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fibers. ASCs cultured under strained conditions in media supplemented with TGF-β1 expressed 
α-SMA and h-1calponin at levels nearly comparable to that of the static controls treated with 
TGF-β1. 
Figure 15 depicts immunofluorescence staining results for h1-calponin. Control ASCs & 
strained ASCs (with or without TGF-β1) were stained positive for calponin. Similar to the 
expression of α-SMA, srain alone reduced the expression of calponin significantly, whereas the 
addition of TGF-β1 increased the expression drastically. 
 
CON CON+TGF-β1
STR STR+TGF-β1  
Figure 15 Immunofluorescence staining for h1-calponin. 
 
Again, the immunofluorescence staining results for calponin were confirmed with 
Western blot analysis. The bands were quantified using the same methods. Similarly, the 
addition of TGF-β1 induced a 2 fold increase over the control. Strain alone reduced the 
expression of calponin by 40%. Strain & TGF-β1 combined brought the expression of calponin 
back to about 3.5 fold over the control. 
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Figure 16a Western blot analysis for calponin further confirmed the immunofluorescence 
staining results. 
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Figure 16b Western blot analysis for calponin further confirmed the immunofluorescence 
staining results. The data shown here were based on three experiments (n=3) with cells from two 
donors. Overly saturated bands may have resulted in an underestimated difference. 
 
4.3.3 Summary of Results 
In this study, we demonstrated that cyclic strain inhibited proliferation, and caused 
alignment of the cells and of the F-actin cytoskeleton perpendicular to the direction of strain. 
Cyclic strain also regulated α-SMA and h1-calponin protein expression in ASCs. 10% uniaxial 
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cyclic strain alone down-regulated α-SMA and h1-calponin protein expression in ASCs, whereas 
TGF-β1 up-regulated the expression of α-SMA and h1-calponin. In addition, F-actin staining 
results of control ASCs or strained ASCs treated with TGF-β1 were counter-intuitive. Not only 
were increased F-actin stress fibers not observed in TGF-β1 treated cells, F-actin staining results 
also did not correspond with α-SMA or calponin immunostaining results. 
4.4 CARDIOMYOGENIC DIFFERENTIATION POTENTIAL OF ASCS 
4.4.1 Effects of 5-azacytidine on ASCs 
We have conducted studies on the potential of ASCs to differentiate into cardiomyocyte-
like cells via exposure to 5-azacytidine. ASCs were seeded at different cell densities, and were 
treated with 5-azacytidine for 24 hr, 1 week, 4 weeks, and up to 8 weeks using repeated exposure 
and single exposure treatment methods as described in literature. Spontaneously and 
synchronously pulsating cardiomyocyte-like cells were not observed. Figure 17 depicts phase-
contrast images of control ASCs and ASCs treated with 10µM of 5-aza after 4 weeks in culture 
(via repeated 5-azacytidine treatment). As shown in this figure, ASCs treated with 5-aza seemed 
less confluent and demonstrated a different morphology. ASCs that were repeated exposed to 5-
azacytidine for 4 weeks were indistinguishable from control ASCs. 
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CON 5-aza (10µM)  
Figure 17 Phase-contrast images of control ASCs and ASCs treated with 10µM of 5-aza for 3 
weeks in culture (from repeated treatment group). ASCs treated with 5-aza are less confluent and 
have a different morphology. 
 
Untreated ASCs and 5-azacytidine treated ASCs were stained for cytoskeletal protein and 
early smooth muscle cell marker α-SMA. Control ASCs and ASCs that were transiently exposed 
to 5-azacytidine expressed high levels of this protein, whereas the expression of α-SMA was 
significantly reduced in ASCs that were repeated treated with 5-azacytidine (as shown in Figure 
18). Western blot analysis further confirmed the reduction in α-SMA expression (Figure 19).  
Control 24hr Transient Repeated  
Figure 18 Immunofluorescence staining results for α-SMA (green), counter-stained with DAPI 
(blue). (A) Control ASCs that were cultured in the absence of 5-azacytidine for 4 weeks. (B) 
ASCs that were transiently exposed to 5-azacytidine for 24 hrs, and cultured in regular plating 
media with 10% serum for 4 weeks. (C) ASCs that were repeatedly treated with 5-azacytidine for 
4 weeks in culture. 
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α-SMA
GAPDH
CON 24hr Transient Repeated
 
Figure 19 Western blot results for α-SMA. There was a significant reduction in the expression 
 of α-SMA in ASCs that were repeatedly exposed to 5-azacytidine. 
 
 
 
 
 
 
 
 
Figure 20 Optical density (OD) values of Western blot bands for α-SMA were measured and 
quantified. The OD value of α-SMA was divided by the OD value of GAPDH for bands 
representing each treatment group. There was no significant difference in the expression of α-
SMA between CON and ASCs that were transiently exposed to 5-azacytidine. ASCs that were 
repeatedly treated with 5-azacytidine showed a significant decrease (-48%) in α-SMA expression 
as compared with control ASCs. 
 
Control ASCs and 5-azacytidine treated ASCs were also stained for gap junction protein 
connexin-43. After 1 week in culture, control ASCs and ASCs that were transiently exposed to 
5-azacytidine expressed low levels of connexin-43. The expression of Cx-43 was merely present 
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in ASCs that were repeatedly exposed to 5-azacytidine after 1 week (3 treatments of 5-
azacytidine). After 4 weeks in culture, there was a significant increase in the expression of Cx-43 
in all treatment groups, as shown in Figure 21. The expression of Cx-43 seemed independent of 
exposure to 5-azacytidine, but dependent on cell density or confluency. 
 
 
 
 
 
Figure 21 Western blot results for gap junction protein connexin 43. GAPDH was used as an 
 internal loading control. There was a significant increase in the expression of Cx-43 after 
4 weeks in culture. The increase in Cx-43 protein expression was dependent on cell density. 
 
 
 
 
 
 
 
 
 
Figure 22 Ratios of OD values (Cx-43/GAPDH). Data were collected from three separate 
experiments. There was a 30% reduction in the expression of Cx-43 in ASCs that were repeated 
exposed to 5-azacytine after 1 week or 4 weeks in culture. A 70% increase in Cx-43 expression 
was noted between corresponding 1 week and 4 week samples from all treatments.  
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 Control ASCs and 5-azacytidine treated ASCs were also stained for cardiac specific 
markers sarcomeric α-actinin (Figure 23). Control ASCs, ASCs that were transiently or repeated 
exposed to 5-azacytidine for 4 weeks were negative for α-actinin. Western blot data confirmed 
the negative findings (Figure 24). The 5-azacytidine treated ASCs were also negative for cardiac 
troponin I and troponin T. Sections of the human heart were used as positive control. Protein 
collected from cultured fetal human cardiomyocytes was used as positive control for Western 
blot analysis.   
CON 24hr Transient
Repeated Human Heart  
Figure 23 Immunofluorescence staining results for  α-actinin (green), counter-stained with DAPI 
(blue).  (A) Control ASCs that were cultured in the absence of 5-azacytidine for 4 weeks.  (B) 
ASCs that were transiently exposed to 5-azacytidine for 24 hrs, and cultured in regular plating 
media with 10% serum for 4  weeks. (C) ASCs that were repeatedly treated with 5-azacytidine 
for 4 weeks in culture. (D) Human heart (positive control). 
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Figure 24 Western blot analysis results for α-actinin. α-actinin protein expression was 
undetected in control ASCs and 5-azacytidine treated ASCs. 
 
The expression of cardiac specific transcription factors Nkx2.5 and GATA4 in control 
ASCs and 5-azacytidine treated ASCs was also examined. ASCs (regardless of exposure to 5-
azacytidine) were negative for both Nkx2.5 and GATA4, as shown in Figure 25 and Figure 26.  
 
Nkx2.5
GAPDH
CM CON 24hr Transient Repeated
 
Figure 25 Gene expression of cardiac transcription  factor Nkx2.5. Control ASCs and 5-
azacytidine treated ASCs were negative for Nkx2.5. cDNA from fetal human heart was used as 
the positive control. 
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Figure 26 Gene expression of cardiac transcription  factor GATA4. Control ASCs and 5-
azacytidine treated ASCs were negative for GATA4. 
 
 
4.4.2 Summary of Results 
In summary, repeated exposure of ASCs to 5-azacytidine inhibited cell growth and 
significantly reduced α-SMA protein expression. The expression of gap junction protein 
connexin-43 was up-regulated in ASCs in long term cultures, independent of 5-azacytidine 
exposure, but dependent on cell density. Protein expression of sarcomeric α-actinin, cardiac 
troponin I and troponin T was undetected in 5-azacytidine treated ASCs. Expression of cardiac 
transcription factors Nkx2.5 and GATA4 was also undetected. 
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5.0  DISCUSSION 
5.1 RESPONSE OF ASCS TO TGF-Β1, PDGF-BB, BME, AA, RA, AND D-CAMP   
There is an extensive body of literature describing the role of specific growth factors or 
cytokines in the regulation of smooth muscle cell differentiation. Some of these factors include 
transforming growth factor-β1 (TGF-β1), platelet-derived growth factor BB (PDGF-BB), β-
mercaptoethanol (BME), ascorbic acid (AA), retinoic acid (RA), and dibutyryl-cyclic adenosine 
monophosphate (d-cAMP). Differentiating smooth muscle is characterized by the sequential 
appearance of cytoskeletal and contractile proteins to yield the variety of phenotypes that typify 
adult smooth muscle cells [78]. One of the first smooth muscle cell markers to be expressed 
during smooth muscle cell differentiation is α-smooth muscle actin (α-SMA) [78].  
 The specific objectives of the first aim of this thesis work were to investigate the effects 
of TGF-β1, PDGF-BB, BME, AA, RA, and d-cAMP on the expression of α-SMA during ASC 
differentiation. These growth factors have been demonstrated to either up or down-regulate α-
SMA expression in marrow-derived MSCs and embryonic progenitor cells in several previous 
studies [64-70]. 
Protein characterization conducted in this study demonstrated that the expression of α-
SMA in ASCs significantly increased in the presence of TGF-β1, while α-SMA expression only 
slightly increased with RA, BME and AA. Exposure to PDGF-BB, RA and d-cAMP resulted in a 
dramatic decrease in the expression of α-SMA.  
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5.1.1 Transforming Growth Factor-β1   
Transforming growth factor-β1 is secreted by many cell types, including vascular 
endothelial and smooth muscle cells, and essentially all cells have receptors for TGF-β1   [97]. 
TGF-β1 can have an inhibitory effect on smooth muscle cell proliferation, but can also have a 
mitogenic effect on the cells under certain conditions [98]. There are reports that TGF-β1 can 
increase extracellular matrix production by smooth muscle cells [99-100]. Contractile protein 
expression can be increased by TGF-β1, not only in SMCs, but also in neural crest cells, 
embryonic stem cells, and mesenchymal stem cells [101, 68-69], suggesting that TGF-β1 may 
play a role in vascular tissue development. The effect of TGF-β1 in up-regulating the expression 
of α-SMA in ASCs as observed in this study is consistent with prior findings of similar effects of 
TGF-β1 on other cell types, including progenitor cells.    
5.1.2 Platelet-derived Growth Factor BB  
Platelet-derived growth factor is secreted by a number of cell types found in the 
vasculature, including endothelial cells, smooth muscle cells, and activated macrophages [97], 
and PDGF-BB can produce a mitogenic response in cultured VSMCs [98]. PDGF-BB has also 
been shown to have potent effects on cells of mesenchymal origin [102]. There is growing 
evidence that PDGF-BB is involved in the pathogenesis of arteriosclerosis, in which PDGF is 
hypothesized to promote smooth muscle cell migration, proliferation and matrix production 
typically associated with intimal thickening [98]. Li et al. reported that PDGF-BB caused 
decreased α-SMA expression in vascular smooth muscle cells via a pathway separate from its 
effect on proliferation (which is hypothesized to be responsible for the shift toward the synthetic 
 62 
phenotype) [100]. Consistent with literature findings, we have observed that ASCs respond to 
PDGF-BB in similar fashions as VSMCs and MSCs. After exposure to PDGF-BB for two weeks, 
ASCs were highly proliferative, and demonstrated a marked decrease in the expression of α-
SMA. 
5.1.3 Retinoic Acid 
Retinoic acid, an active form of retinoids, is involved in signal transduction pathways 
regulating embryonic development [103]. Retinoids influence differentially the features of 
distinct SMC phenotypes. Additionally, all-trans retinoic acid can modulate proliferation, 
migration, plasminogen activator activity, and α-smooth muscle actin expression in SMCs [104]. 
d-cAMP can act synergistically with RA in several molecular and developmental processes; 
however, molecular mechanisms of cooperation between RA and d-cAMP is not known. Suzuki 
et al. [66] have shown that the treatment of a P19 cell line resulted in significant smooth muscle 
cell differentiation enhancement, whereas Drab et al. [67] reported the formation of 
spontaneously contracting smooth muscle cell-like cell clusters in the presence of high 
concentration retinoic acid and d-cAMP. These results were not observed in this study, 
indicating that ASCs and totipotent embryonic stem cells are fundamentally different, and 
respond differently to biochemical stimuli such as RA and d-cAMP. A slight increase in α-
smooth muscle actin expression was observed in ASCs cultured with RA alone, whereas a 
significant decrease in α-smooth muscle actin expression was noted with cells treated with RA 
and d-cAMP. 
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5.1.4 Ascorbic Acid  
L-Ascorbic acid (L-Asc) and its derivatives, L-Ascorbic acid 2-phosphate, have been 
shown to have some effects on the cardiovascular system, including growth inhibition of VSMCs 
[105]. Moreover, Arakawa et al. [64-65] have found that L-Asc stimulates the differentiation of 
pluripotent stem cells into smooth muscle-like cells, which is similar to what we have observed 
(a significant increase in the expression of α-SMA) when culturing ASCs in the presence of L-
Asc and BME (a reducing agent that breaks down toxic cell metabolites).  
5.1.5 Conclusion and Future Studies  
It is poorly understood what factors are involved in mesenchymal cell differentiation 
toward the SMC lineage. The complete set of biochemical and mechanical signals that regulate 
SMC function in vivo is not clear, though it has been demonstrated that changes in environmental 
conditions can lead to phenotype shifts. Removal of VSMCs from their native environment alters 
the biochemical and mechanical signals responsible for maintaining normal cell function, 
causing a shift from a quiescent, contractile phenotype to a more proliferative, synthetic state.  
The function of SMCs in their native environment is influenced by a wide variety of 
biochemical factors, many of which interact to create complex signaling mechanisms. Recreating 
this level of control in vivo is a challenging task. It is possible to use selected biochemicals to 
modulate cell function and phenotype for vascular tissue engineering applications; however it is 
difficult to select the appropriate bioactive molecules for the homing of these cells into cells of 
the vasculature. Factors that need to be taken into account include optimal concentration of each 
molecule, duration, succession of incidence. Furthermore, it may not be possible for such simple 
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growth factor-driven differentiation events to occur in vitro in the absence of other important 
physiological signals experienced by cells in their native environment. Future studies include 
examining the role of hemodynamic forces in cell differentiation and phenotype modulation.  
5.2 EFFECTS OF MECHANICAL STRAIN ON ASCS 
It has been shown that ASCs can differentiate into a variety of cells via an array of 
bioactive molecules that have been well defined, and have immense potential as a cell source for 
regenerative medicine. However, it is not well known how these cells respond to the forces that 
they would be subjected to in vivo. A recent study by Knippenberg et al. [106] examined 
whether ASCs are responsive to mechanical loading via pulsating fluidflow (PFF) and reported 
osteogenic differentiation of ASCs. This study was one of the first to address the effects of 
mechanical forces on ASCs; however, the effects of other types of forces such as cyclic strain on 
ASCs remain unexplored. 
Prior studies have demonstrated that MSCs in long-term culture can differentiate into 
SMCs and that TGF-β1, enhances the expression of SMC-specific markers [68, 107]. The effects 
of the vascular mechanical environment on MSCs have been recently examined [81-83]. 
Hamilton et al. [81] demonstrated that cyclic strain resulted in the expression of vascular smooth 
muscle α-actin and h1-calponin in rat bone marrow-derived progenitor cells. Kobayashi et al. 
[82] reported that long term incubation and subsequent compressive strain, or cyclic uniaxial 
strain alone (not equiaxial strain) promotes the expression of smooth muscle-like properties in 
MSCs [83]. 
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In aim 2 of this thesis work, we demonstrated that mechanical strain regulated α-SMA 
and calponin protein expression in ASCs and that uniaxial strain alone induced a decrease in the 
α-SMA and calponin protein expression. Our results suggest that uniaxial strain downregulates 
the expression of SMC contractile marker in ASCs. Cyclic strain of 10% at 1Hz for 7 days 
downregulated α-SMA and h1-calponin protein expression in ASCs, whereas TGF-β1 
upregulated α-SMA expression and resulted in prominent actin stress fibers.  
5.2.1 Importance of Cell Orientation on Cellular Response to Strain 
Mechanical forces have been shown to induce various biological responses, including cell 
reorientation, actin cytoskeletal remodeling, altered cell proliferation, gene expression, and 
protein synthesis [108]. It is also well recognized that mechanical forces can alter cellular 
phenotype. Various in vitro model systems, such as the Flexcell Strain Unit used in this study, 
have been developed to examine the effects of mechanical forces on cells. Typically, these 
systems utilize deformable materials with smooth surfaces to culture cells. There are limitations 
to these systems. Cells randomly orient themselves prior to mechanical stimulation, and once 
exposed to mechanical strain, cells reorient in a direction with minimal deformations to minimize 
strain experienced by the cell bodies. Smooth culture surfaces do not allow control of cell 
orientation [108]. 
We postulate that the dramatic decrease of protein expression under uniaxial cyclic strain 
alone may be partly due to the reorientation of cells cultured on smooth surfaces, as reported by 
other investigators [83]. It may be possible that sustained uniaxial strain was not sensed by the 
cells. Cells in vivo are well organized, have a defined shape or morphology, and remain in a 
certain orientation. For example, vascular SMCs in their native environment assume an 
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elongated morphology, align in the circumferential direction, and are parallel to the direction of 
strain exposed on them due to the pulsatile nature of blood flow. Additionally, vascular SMCs 
upregulate their expression of contractile SMC markers when exposed to strain. Therefore, the 
responses of cells to uniaxial strain may not closely mimic those observed in vivo. 
As cell organization, morphology, and orientation appear to influence cell function and 
phenotype, it is necessary to utilize an in vitro system that can readily mimic in vivo mechanical 
loading conditions. Using microfabrication technology, investigators have developed 
microgrooved silicone surfaces and/or extracellular matrix micropatterning to keep cells ranging 
from human patellar tendon fibroblasts [108] to vascular SMCs and cardiomyocytes [109-110] 
aligned in the direction of strain in vitro while exposed to repetitive mechanical stretching.  
Our results also suggest that although uniaxial cyclic strain closely mimics the type of 
mechanical strain experienced by native vascular SMCs, and upregulates SMC specific protein 
markers when applied to bone marrow-derived MSCs [81-83], it is possible that the parameters 
(i.e., 10% strain at 1Hz, 7 days) of mechanical stimulation used in this experiment may not be 
optimal for ASCs. 
5.2.2 Role of TGF-β1 and Mechanical Strain 
The last variable in our study, growth factor addition, is as important as both the 
mechanical stimulation and surface matrix. We incorporated TGF-β1 into our studies, both with 
and without strain. Transforming growth factor-β is secreted by many cell types, and essentially 
all cells have receptors for TGF-β. TGF-β is secreted by cells in an inactive form and must be 
cleaved by the action of proteolytic enzymes or other methods to become active. Complex 
positive and negative control mechanisms exist to regulate the activation and function of TGF-β 
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in vivo. TGF-β plays an important role in cell growth, differentiation, migration, and 
extracellular matrix production. It is unclear from our study whether mechanical loading is an 
independent factor in the regulation of smooth muscle specific protein expression or its effect is 
mediated by factors such as TGF-β1. Grainger et al. [111] and Hautmann et al. [112] have 
reported that the SMC contractile phenotype is regulated by TGF-β, and that TGF-β can increase 
α-SMA expression in MSCs [68-69]. The addition of TGF-β1 to each of the different culture 
conditions in our experiments caused a significant increase in the protein expression of α-SMA 
and h1-calponin. 
5.2.3 Conclusion and Futures Studies 
In summary, the results of this study indicate that cyclic mechanical strain influences 
ASC orientation, growth and phenotype. The effect of mechanical forces on the growth and 
differentiated properties of ASCs is not well understood. Little is known about how individual 
cells respond to mechanical strain or the underlying molecular mechanisms by which mechanical 
events are transduced into physiological responses. Recent studies, together with our current 
results, suggest that the type of mechanical strain, matrix environment, and/or additional 
chemical factors may result in different cellular responses. Future studies include controlling cell 
orientation in vitro to ensure sustained uniaxial cyclic strain is sensed by the cells, optimizing the 
magnitude and frequency of strain, and duration of experiment. 
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5.3 CARDIOMYOGENIC DIFFERENTIATION POTENTIAL OF ASCS 
5.3.1 Cardiomyogenic Differentiation in Marrow-derived MSCs via 5-Azacytidine 
Stimulation  
The ability of 5-azacytidine to induce cardiomyogenic gene and protein expression in 
stem cells or progenitor cells has been well-documented by several different groups over the last 
few decades. Although Constantinides et al. [113] were the first to describe the appearance of 
multinucleated striated muscle cells in non-myoblast precursors following 5-azacytidine 
treatment, it was Makino et al. [84] who initially described the appearance of cardiomyocytes 
from immortalized murine bone marrow-derived MSCs. Following this report, Tomita et al. 
[114] reported that rat MSCs in a primary culture were also capable of achieving this phenotype. 
However, recent studies by other investigators have failed to reproduce these findings. Zhang et 
al. reported passage-restricted differentiation potential of rat MSCs into cardiomyocyte-like cells 
[115]. Only P4 but not P1 and P8 bone marrow-derived rat MSCs showed formation of myotubes 
and expressed cardiomyocyte-specific markers after exposure to 5-azacytidine. In addition, Liu 
et al. were unable to obtain spontaneously beating cells after exposing primary and passaged 
Wistar rat MSCs to various concentrations of 5-azacytidine using single or repeated treatment 
methods [116].  
 
5.3.2 Effects of 5-azacytidine on ASCs 
Bone marrow is not the only source of cells that are capable of cardiomyogenic 
differentiation. Recently, three groups have reported in vitro differentiation of stem cells derived 
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from the adipose tissue into cardiomyocyte-like cells [40, 95-96]. Although distinct induction 
methods were used, each group reported spontaneously beating cells and evidence of expression 
of cardiomyocytic cell surface markers. Planat-Bernard et al. [95] cultured fresh murine ASCs in 
semi-solid methylcellulose medium supplemented with cytokines, and observed colonies of 
beating cells after three weeks in culture. However, passaged cells could not be induced into 
beating cell colonies exhibiting molecular and electrophysiologic properties of cardiomyocytes 
using identical semi-solid medium. Gaustad et al. [96] reported protein expression of cardiac 
specific markers in human ASCs after transient exposure to nuclear and cytoplasmic extracts of 
rat cardiomyocytes.     
Rangappa et al. [40] reported that mesenchymal stem cells derived from rabbit fatty 
tissue could transform into contractile cardiomyocyte-like cells via exposure to 5-azacytidine. A 
similar approach was applied in the present study as an attempt to further assess the effects of 5-
azacytidine on the fate of stem cells derived from human adipose tissue. The novel conversion of 
rabbit ASCs into beating cardiomyocyte-like cells as reported by Rangappa et al. was not 
observed in our study with human ASCs. Three different concentrations of 5-azacytidine (5, 9, 
10μM), different cell densities, and treatments methods were examined, but neither the formation 
of myotubes nor presence of spontaneously beating cells were noted after 8 weeks in culture. 
Protein expression of cardiac-specific markers such as α-actinin, cardiac troponin I, troponin T 
was undetected. Expression of cardiac transcription factors Nkx2.5 and GATA4 were also 
absent. The specificity and reliability of the detection techniques were confirmed using human 
fetal cardiomyocytes. Gap junction protein connexin-43 was present, although the level of 
expression was independent of exposure to 5-azacytidine, but dependent on cell 
density/confluency. Cytoskeletal protein α-SMA was present in control ASCs and 5-azacytidine 
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treated ASCs, although the expression of α-SMA was significantly reduced in ASCs that were 
repeated exposed to 5-azacytidine.      
5.3.3 Non-specific Activity of 5-azacytidine 
5-azacytidine is a chemical analogue of the cytosine nucleoside used in DNA and RNA. 
Cells in the presence of 5-azacytidine incorporate it into DNA during replication and RNA 
during transcription. The incorporation of 5-azacytidine into DNA or RNA inhibits 
methyltransferase thereby causing demethylation in that sequence, affecting the method that cell 
regulation proteins are able to bind to the DNA/RNA substrate [117].  
Genetic reprogramming by 5-azacytidine may not be specific. As a cytosine analogue, 5-
azacytidine has been reported to cause phenotypical changes in a number of cell types by 
activating novel gene expressions both in vitro and in vivo [118]. Treatment with 5-azacytidine 
causes phenotypic conversions of fibroblasts to adipocytes and myocytes [119] and induces 
erythroid differentiation in erytholeukemia cells [120]. Although the precise mechanisms and 
effects of 5-azacytidine are not well-understood, it has been suggested that the cytosine analogue 
may activate a number of silent genes by inhibiting DNA methylation or induce changes in other 
specific genes to trigger their response to exogenous stimulation [121]. As Liu et al. [116] have 
speculated, it is possible that 5-azacytidine-induced cardiomyogenic differentiation can only 
occur in certain immortalized cell lines of specificanimal species due to random reprogramming 
of gene expression in response to the effects of 5-azacytidine.     
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5.3.4 Conclusion and Future Studies 
DNA demethylation agent 5-azacytidine has been widely described in literature as an 
effective chemical stimulus used to promote cardiomyogenic differentiation in various cell types, 
ranging from embryonic stem cells, P19 cells, bone marrow-derived mesemchymal stem cells, 
and recently to adipose-derived stem cells. Of interest and importance is the observation that 
human ASCs may not be capable of differentiating into cardiomyocyte-like cells via exposure to 
5-azacytidine. Our results indicate that exposure to 5-azacytidine is not likely to be clinically 
applicable due to its low efficacy and potentially harmful effects of its non-specific 
demethylating activity.  
Future studies include examining the effects of other chemical stimuli and direct cell-cell 
contact on ASC differentiation along the cardiomyogenic lineage. A recent study conducted by 
Behfar et al. [127] identified an array of recombinant cardiotrophic agents that were successful 
in collectively inducing a cardiomyogenic phenotype in human bone marrow-derived 
mesenchymal stem cells after 21 days in culture. The cardiotrophic agents employed include 
transforming growth factor-β1, bone morphogenetic protein 2, insulin-like growth factor 1, 
fibroblast growth factor 4, interleukin-6, leukemia inhibitory factor, α-thrombin, vascular 
endothelial growth factor A, tumor necrosis factor-α, and retinoic acid [127]. It is possible that 
ASCs may respond similarly to the cardiotrophic agents as the marrow-derived MSCs.  
 In addition to chemical stimuli, it has been hypothesized that intercellular crosstalk may 
play a critical role in directing the progression of stem cells into differentiated cells [93-94]. 
Recent studies have shown that intercellular interaction between adult human mesenchymal stem 
cells and adult human cardiomyocytes could induce stem cells to acquire the phenotypical 
characteristics of functional cardiomyocytes. By co-culturing human MSCs with human 
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cardiomyocytes, it was demonstrated that MSCs acquired a cardiomyocyte-like phenotype 
characterized by the expression of myosin heavy chain and troponin T [93-93]. However, when 
MSCs were incubated with a cardiomyocyte-conditioned medium, cardiac specific protein 
expression was not observed. Thus, direct cell-to-cell contact may be obligatory in relaying 
cardiac environmental or microenvironmental signals for successful MSC differentiation along 
the cardiomyogenic lineage [93-94]. These data suggest that human ASCs may also benefit from 
environmental cues resulting from direct cell-cell contact with cultured cardiomyocytes. 
5.4 SUMMARY 
In summary, adipose tissue, like bone marrow, contains a population of cells that has 
extensive self-renewal capacity and the ability to differentiate along multiple lineages. These 
cells can be obtained in large numbers at high frequency from a tissue source that can be 
extracted in large quantities with minimal morbidity. Like marrow-derived mesenchymal stem 
cells, adipose-derived stem cells have been shown to differentiate into cells that express markers 
of endothelial, smooth muscle, and cardiomyocytic differentiation.  
The differential response of ASCs to biomolecules such as BME, AA, and RA suggests 
that although adipose tissue and bone marrow are both derived from embryonic mesoderm and 
contain a heterogeneous stromal cell population and share many similarities, stem cells isolated 
from adipose tissue and bone marrow are fundamentally different and respond to exogenous 
biochemical stimulation differently. In addition, our data on the effects of cyclic strain on ASCs 
led us to conclude that ASCs also respond to mechanical stimulation differently than marrow-
derived MSCs. Furthermore, species differences and non-specific activity of DNA demethylation 
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agent 5-azacytidine could have led to the unexpected results with cardiomyogenic differentiation 
of human ASCs.  
This study has advanced our understanding of the biochemical and mechanical regulation 
of adipose-derived stem cells. These findings, combined with the high yield of cells from 
adipose, suggest that adipose tissue represents a potential clinically useful source of cells for 
cellular therapy and tissue engineering applications targeting at cardiovascular disorders. 
Although the effects of mechanical loading, exogenous biochemical stimulation, and the 
crosstalk between mechanical and chemical factors still remain to be elucidated, further 
investigation is underway.    
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